Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

GUARD-QUANTUM is a prospective, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study. The rationale behind studying this combination lies in the potential additive or synergistic benefits that may arise from concurrently targeting androgen receptor signaling pathways and bone metastases.

NCT Number	NCT07717099
Lead Sponsor	Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD Collaborators: Bayer, MFAR
Conditions	Metastatic Hormone-Sensitive Prostate Cance
Enrollment	50 participants
Start Date	2026-09
Primary Completion	2029-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-21